Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Edwards Lifesciences on Tuesday, setting a price target of $125, which is approximately 21.47% above the present share price of $102.91.
Antalffy expects Edwards Lifesciences to post earnings per share (EPS) of $0.54 for the third quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Strong Buy rating of shares in Edwards Lifesciences, with an average price target of $104.5.
The analysts price targets range from a high of $112 to a low of $93.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $1.22 billion and a net profit of $385.4 million. The company's market cap is $63.97 billion.
According to TipRanks.com, Leerink Partners analyst Danielle Antalffy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.9% and a 63.80% success rate.
Incorporated in 1958, California-based Edwards Lifesciences Corp (NYSE:EW). is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.